<DOC>
	<DOC>NCT02276027</DOC>
	<brief_summary>To investigate the anti-tumor activity of single agent BYL719, INC280, LDK378 and MEK162</brief_summary>
	<brief_title>A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Advanced (stage IIIB or stage IV) NSCLC Must have specific molecular alterations Symptomatic central nervous system (CNS) metastases which are neurologically unstable or requiring increasing doses of steroids within the 4 weeks prior to study entry to control their CNS disease Radiation therapy within ≤ 4 weeks prior to study entry, with the exception of limited field palliative radiotherapy for bone pain relief. Any other malignancies within the last 5 years before study entry Major surgery ≤ 2 weeks prior to study entry or who have not recovered from side effects of such therapy Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma lung cancer,squamous cell lung carcinoma, NSCLC</keyword>
</DOC>